



04 APR 22 PM 3:46

February 26, 2004

Office of the Secretary
Suite 232 Hart Building
U.S. Senate
Washington, DC 25010-7116

Dear Sirs:

I am writing on behalf of the President of our firm, Donald N. Muse. He has been in the hospital since the beginning of February, and consequently has not been able to file the required Lobbying Report that was due on February 17.

Under normal circumstances, he would report his activities for the following groups:


Data Nice Associates, Inc. (# 26240-90)
Pharmaceutical Research and Manufacturers of America (# 26240-51)
American Chiropractic Association (# 26240-12)
American Orthotic and Prosthetic Association (# 26240-113)

Dr. Muse will probably continue to recover from his illness at home for the next couple weeks, after which he will be coming into the office on a part time basis and will be able to complete the Lobbying Report for the second half of 2003.

Please let me know if this is acceptable, and if anything else needs to be done at this end until this can be resolved.

Thank you for your help.

Sincerely,


Elizabeth Scattergood Segall
Information Manager

 1775 I Street, NW • Suite 520 • Washington, DC 20006 • Tel 202-496-0200 • Fax 202-496-0201 • www.muse-associates.com

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

04 APR 2003

LOBBYING REPORT


Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Muse & Associates			
2. Address <input type="checkbox"/> Check if different than previously reported 1775 I Street, NW, Suite 520, Washington, DC 20006			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Donald N. Muse	Telephone (202) 496-0200	E-mail (optional)	5. Senate ID # 26241
7. Client Name <input type="checkbox"/> Self Pharmaceutical Research and Manufacturers of America			6. House ID # 32526

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December 31)
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying **INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input checked="" type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code</p>
---	---

Signature


 Filing #e5e1a0a5-eb7d-4f1a-9016-f33c0a6b4da1 - Page 3 of 6

Printed Name and Title

Donald N. Muse, President

LD-2 (REV. 6/98)

P.

Registrant Name Muse & Associates Client Name Pharmaceutical Research and Manufacturers c

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Prepared materials on effect of Prescription Drug Benefit legislation on States' Medicaid programs

17. House(s) of Congress and Federal agencies contacted

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Donald N. Muse	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature  Date 3-1-12

